Sign in to view content

Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy

Scott D Walter, MD, MSc, FASRS

Video
Published 2021

Related

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019
Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2017
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more